St John's Wort increases expression of P-glycoprotein: Implications for drug interactions

被引:193
作者
Hennessy, M
Kelleher, D
Spiers, JP
Barry, M
Kavanagh, P
Back, D
Mulcahy, F
Feely, J
机构
[1] Trinity Coll Dublin, Dept Pharmacol & Therapeut, Dublin, Ireland
[2] Trinity Coll Dublin, Dept Clin Med, Dublin, Ireland
[3] St James Hosp, Dept Genito Urinary Med, Dublin 8, Ireland
[4] Univ Liverpool, Dept Pharmacol, Liverpool L69 3BX, Merseyside, England
关键词
flow cytometry; P-glycoprotein; ritonavir; St John's Wort;
D O I
10.1046/j.0306-5251.2001.01516.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims St John's Wort (SJW) is widely used in the treatment of depression but concerns have been raised about its potential to interact with other drugs. Co-administration with SJW has resulted in significant reductions in trough plasma concentrations of indinavir and cyclosporin [1, 2]. Induction of cytochrome P450 3A4 (CYP3A4) has been implicated as the most likely interaction mechanism. However, the magnitude of the interaction seen in clinical practice is greater than that predicted by in vitro studies suggesting additional interaction mechanisms may exist. As indinavir and cyclosporin are substrates for both CYP3A4 and the multi drug transporter P-glycoprotein we hypothesized that modulation of P-glycoprotein expression and function by SJW may contribute to the development of potentially harmful drug-drug interactions. Methods Healthy volunteers were randomized to either SJW (0.15%) 600 mg three times daily for 16 days (n=15) or placebo (n=7). Blood samples were obtained for P-glycoprotein expression and function at baseline, 16 and 32 days post treatment. Peripheral blood lymphocytes (PBMCs) were isolated by Ficoll density gradient centrifugation, fixed and permeabilized. Cells were stained with a P-glycoprotein specific antibody, quantified by flow cytometry and median fluorescence intensity (MFI) values obtained. Vimentin and IE (nonsense antibody) were used as controls. The presence of the MDR 1 gene product was confirmed by RT-PCR. P-glycoprotein mediated drug efflux was determined as a function of rhodamine efflux in the absence and presence of ritonavir. Data are expressed as mean+/-s.d. and were subjected to nonparametric analysis. Results P-glycoprotein expression increased 4.2 fold from baseline in subjects treated with SJW (7.0+/-1.9 vs 29.5+/-14.3 (MFI); P<0.05). There was no effect with placebo (5.1+1.3 vs 6.0+/-1.9 MFI). SJW increased P-glycoprotein mediated rhodamine efflux (reduced ratio) compared with baseline (0.12+/-0.04 vs 0.24+/-0.18 P<0.05). There was no change with placebo. Ritonavir (5 muM) inhibited P-glycoprotein mediated efflux in both groups producing greater intracellular accumulation of rhodamine. However, this effect was attenuated following treatment with SJW (23.9+/-15.3% vs 75.4+/-16.4% P<0.05). Conclusions SJW increased expression and enhanced the drug efflux function of the multi drug transporter P-glycoprotein in PBMCs of healthy volunteers. This may represent a second mechanism for the drug-herb interactions seen in clinical practice and account for the discrepancies between in vitro and in vivo data. Since P-glycoprotein and CYP3A4 have distinct though overlapping substrates, patients receiving drugs, which are P-glycoprotein substrates should be warned against self-medication with SJW as clinically significant drug interactions may occur.
引用
收藏
页码:75 / 82
页数:8
相关论文
共 48 条
[21]   The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module [J].
Goodwin, B ;
Hodgson, E ;
Liddle, C .
MOLECULAR PHARMACOLOGY, 1999, 56 (06) :1329-1339
[22]   The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin [J].
Greiner, B ;
Eichelbaum, M ;
Fritz, P ;
Kreichgauer, HP ;
Von Richter, O ;
Zundler, J ;
Kroemer, HK .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :147-153
[23]   3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine [J].
Gulick, RM ;
Mellors, JW ;
Havlir, D ;
Eron, JJ ;
Meibohm, A ;
Condra, JH ;
Valentine, FT ;
McMahon, D ;
Gonzalez, C ;
Jonas, L ;
Emini, EA ;
Chodakewitz, JA ;
Isaacs, R ;
Richman, DD .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (01) :35-39
[24]   Ritonavir - Clinical pharmacokinetics and interactions with other anti-HIV agents [J].
Hsu, A ;
Granneman, GR ;
Bertz, RJ .
CLINICAL PHARMACOKINETICS, 1998, 35 (04) :275-291
[25]  
Huisman MT, 2000, AIDS, V14, P237, DOI 10.1097/00002030-200002180-00005
[26]   A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples [J].
Illmer, T ;
Schaich, M ;
Oelschlägel, U ;
Nowak, R ;
Renner, U ;
Ziegs, B ;
Subat, S ;
Neubauer, A ;
Ehninger, G .
LEUKEMIA RESEARCH, 1999, 23 (07) :653-663
[27]   Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum) [J].
Johne, A ;
Brockmöller, J ;
Bauer, S ;
Maurer, A ;
Langheinrich, M ;
Roots, I .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (04) :338-345
[28]   St. John's wort for depression - A meta-analysis of well-defined clinical trials [J].
Kim, HL ;
Streltzer, J ;
Goebert, D .
JOURNAL OF NERVOUS AND MENTAL DISEASE, 1999, 187 (09) :532-538
[29]   An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway [J].
Kliewer, SA ;
Moore, JT ;
Wade, L ;
Staudinger, JL ;
Watson, MA ;
Jones, SA ;
McKee, DD ;
Oliver, BB ;
Willson, TM ;
Zetterström, RH ;
Perlmann, T ;
Lehmann, JM .
CELL, 1998, 92 (01) :73-82
[30]   Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin [J].
Kovarik, JM ;
Rigaudy, L ;
Guerret, M ;
Gerbeau, C ;
Rost, KL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (04) :391-400